Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Opinion Fellow Talk

A Look Back at TCT 2018: What I Took Away From the Meeting

Yashasvi Chugh, MD

October 23, 2018

News Opinion Editor's Corner TCT 2018

My Takeaways From TCT 2018: Sunglasses, Shadows, and the COAPT Eclipse

Shelley Wood

October 12, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

Presentation TCT 2018

The Perspective of a Non-Invasive Cardiologist Not So Fast!

Presenter: Sanjay Kaul

September 24, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation Controversies and Advances 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

Video

» Interview

TCT 2017: Dr. C. Michael Gibson talks with Dr. Sanjay Kaul about CANTOS

May 11, 2018

Advertisement

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

A Look Back at TCT 2018: What I Took Away From the Meeting

My Takeaways From TCT 2018: Sunglasses, Shadows, and the COAPT Eclipse

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

The Perspective of a Non-Invasive Cardiologist Not So Fast!

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

TCT 2017: Dr. C. Michael Gibson talks with Dr. Sanjay Kaul about CANTOS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content